Shopping Cart 0
Cart Subtotal
USD 0

Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 2600

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 3500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 4400

Details

Europe amyotrophic lateral sclerosis treatment market accounted for USD 129.5 million in 2020 and will grow by 5.4% annually over 2020-2027 owing to the rising geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies.

Highlighted with 31 tables and 35 figures, this 86-page report Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity is based on a comprehensive research of the entire Europe amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Country.

 

Based on Treatment Type, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Medication

o Riluzole (Rilutek)

o Radicava (Edaravone)

o Tiglutik (Thickened Riluzole)

o Nuedexta

Stem Cell Therapy

Other Treatments

 

Based on ALS Type, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Sporadic ALS

Familial ALS

 

Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other Distribution Channels

 

Geographically, the following national/local markets are fully investigated:

Germany

UK

France

Spain

Italy

Russia

Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

For each key country, detailed analysis and data for annual revenue (USD mn) are available for 2017-2027. The breakdown of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included.

 

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AB Science SA

Amylyx Pharmaceuticals Inc.

Biogen Inc.

Biohaven Pharmaceutical Holding Co., Ltd.

BrainStorm Cell Limited

Corestem, Inc.

F.Hoffmann-La Roche AG

Ionis Pharmaceuticals, Inc.

Mitsubishi Tanabe Pharma Corporation

Otsuka Pharmaceutical Co., Ltd.

Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Table Of Content

Scope

1 Introduction 6

1.1 Industry Definition and Research Scope 6

1.1.1 Industry Definition 6

1.1.2 Research Scope 7

1.2 Research Methodology 10

1.2.1 Overview of Market Research Methodology 10

1.2.2 Market Assumption 11

1.2.3 Secondary Data 11

1.2.4 Primary Data 11

1.2.5 Data Filtration and Model Design 12

1.2.6 Market Size/Share Estimation 13

1.2.7 Research Limitations 14

1.3 Executive Summary 15

2 Market Overview and Dynamics 17

2.1 Market Size and Forecast 17

2.1.1 Impact of COVID-19 on World Economy 18

2.1.2 Impact of COVID-19 on the Market 20

2.2 Major Growth Drivers 22

2.3 Market Restraints and Challenges 26

2.4 Emerging Opportunities and Market Trends 29

2.5 Porter's Fiver Forces Analysis 33

3 Segmentation of Europe Market by Treatment Type 37

3.1 Market Overview by Treatment Type 37

3.2 Medication 39

3.3 Stem Cell Therapy 41

3.4 Other Treatments 42

4 Segmentation of Europe Market by ALS Type 43

4.1 Market Overview by ALS Type 43

4.2 Sporadic ALS 45

4.3 Familial ALS 46

5 Segmentation of Europe Market by Distribution Channel 47

5.1 Market Overview by Distribution Channel 47

5.2 Hospital Pharmacies 49

5.3 Retail Pharmacies 50

5.4 Online Pharmacies 51

5.5 Other Distribution Channels 52

6 European Market 2020-2027 by Country 53

6.1 Overview of European Market 53

6.2 UK 56

6.3 France 58

6.4 Germany 60

6.5 Spain 62

6.6 Italy 64

6.7 Russia 66

6.8 Rest of European Market 68

7 Competitive Landscape 70

7.1 Overview of Key Vendors 70

7.2 New Product Launch, Partnership, Investment, and M&A 73

7.3 Company Profiles 74

AB Science SA 74

Amylyx Pharmaceuticals Inc. 76

Biogen Inc. 77

Biohaven Pharmaceutical Holding Co., Ltd. 78

BrainStorm Cell Limited 79

Corestem, Inc. 80

F.Hoffmann-La Roche AG 81

Ionis Pharmaceuticals, Inc. 82

Mitsubishi Tanabe Pharma Corporation 83

Otsuka Pharmaceutical Co., Ltd. 84

Sun Pharmaceutical Industries Ltd. 85

RELATED REPORTS 86

 


List Of Figure

Figure 1. Research Method Flow Chart 10

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 13

Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 15

Figure 4. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, USD mn 17

Figure 5. Impact of COVID-19 on Business 20

Figure 6. Primary Drivers and Impact Factors of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 22

Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 25

Figure 8. Primary Restraints and Impact Factors of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 26

Figure 9. Investment Opportunity Analysis 30

Figure 10. Porter's Fiver Forces Analysis of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 33

Figure 11. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2020-2027, % of Revenue 37

Figure 12. Contribution to Europe 2021-2027 Cumulative Revenue by Treatment Type, Value (USD mn) and Share (%) 38

Figure 13. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication, 2017-2027, USD mn 39

Figure 14. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Stem Cell Therapy, 2017-2027, USD mn 41

Figure 15. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Treatments, 2017-2027, USD mn 42

Figure 16. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2020-2027, % of Revenue 43

Figure 17. Contribution to Europe 2021-2027 Cumulative Revenue by ALS Type, Value (USD mn) and Share (%) 44

Figure 18. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Sporadic ALS, 2017-2027, USD mn 45

Figure 19. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Familial ALS, 2017-2027, USD mn 46

Figure 20. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2020-2027, % of Revenue 48

Figure 21. Contribution to Europe 2021-2027 Cumulative Revenue by Distribution Channel, Value (USD mn) and Share (%) 48

Figure 22. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Hospital Pharmacies, 2017-2027, USD mn 49

Figure 23. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Retail Pharmacies, 2017-2027, USD mn 50

Figure 24. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Online Pharmacies, 2017-2027, USD mn 51

Figure 25. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Distribution Channels, 2017-2027, USD mn 52

Figure 26. Breakdown of European Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue 54

Figure 27. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value (USD mn) and Share (%) 55

Figure 28. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in UK, 2017-2027, USD mn 56

Figure 29. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in France, 2017-2027, USD mn 58

Figure 30. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Germany, 2017-2027, USD mn 60

Figure 31. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Spain, 2017-2027, USD mn 62

Figure 32. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Italy, 2017-2027, USD mn 64

Figure 33. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Russia, 2017-2027, USD mn 66

Figure 34. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe, 2017-2027, USD mn 68

Figure 35. Growth Stage of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Industry over the Forecast Period 70


List Of Table

Table 1. Snapshot of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Balanced Perspective, 2020-2027 16

Table 2. Growth Rate of World GDP, 2020-2022 19

Table 3. Main Product Trends and Market Opportunities in Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 29

Table 4. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 37

Table 5. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication by Type, 2017-2027, USD mn 40

Table 6. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 43

Table 7. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 47

Table 8. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, USD mn 55

Table 9. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 57

Table 10. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 57

Table 11. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 57

Table 12. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 59

Table 13. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 59

Table 14. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 59

Table 15. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 61

Table 16. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 61

Table 17. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 61

Table 18. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 63

Table 19. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 63

Table 20. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 63

Table 21. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 65

Table 22. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 65

Table 23. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 65

Table 24. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 67

Table 25. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 67

Table 26. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 67

Table 27. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe by Country, 2017-2027, USD mn 69

Table 28. AB Science SA: Company Snapshot 74

Table 29. AB Science SA: Business Segmentation 74

Table 30. AB Science SA: Product Portfolio 75

Table 31. AB Science SA: Revenue, 2017-2019, USD mn 75

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AB Science SA

Amylyx Pharmaceuticals Inc.

Biogen Inc.

Biohaven Pharmaceutical Holding Co., Ltd.

BrainStorm Cell Limited

Corestem, Inc.

F.Hoffmann-La Roche AG

Ionis Pharmaceuticals, Inc.

Mitsubishi Tanabe Pharma Corporation

Otsuka Pharmaceutical Co., Ltd.

Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Company Profile

Company Profile Title

Europe amyotrophic lateral sclerosis treatment market accounted for USD 129.5 million in 2020 and will grow by 5.4% annually over 2020-2027 owing to the rising geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies.

Highlighted with 31 tables and 35 figures, this 86-page report Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity is based on a comprehensive research of the entire Europe amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Country.

 

Based on Treatment Type, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Medication

o Riluzole (Rilutek)

o Radicava (Edaravone)

o Tiglutik (Thickened Riluzole)

o Nuedexta

Stem Cell Therapy

Other Treatments

 

Based on ALS Type, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Sporadic ALS

Familial ALS

 

Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue (USD mn) for 2017-2027 included in each section.

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other Distribution Channels

 

Geographically, the following national/local markets are fully investigated:

Germany

UK

France

Spain

Italy

Russia

Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

For each key country, detailed analysis and data for annual revenue (USD mn) are available for 2017-2027. The breakdown of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included.

 

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AB Science SA

Amylyx Pharmaceuticals Inc.

Biogen Inc.

Biohaven Pharmaceutical Holding Co., Ltd.

BrainStorm Cell Limited

Corestem, Inc.

F.Hoffmann-La Roche AG

Ionis Pharmaceuticals, Inc.

Mitsubishi Tanabe Pharma Corporation

Otsuka Pharmaceutical Co., Ltd.

Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Scope

1 Introduction 6

1.1 Industry Definition and Research Scope 6

1.1.1 Industry Definition 6

1.1.2 Research Scope 7

1.2 Research Methodology 10

1.2.1 Overview of Market Research Methodology 10

1.2.2 Market Assumption 11

1.2.3 Secondary Data 11

1.2.4 Primary Data 11

1.2.5 Data Filtration and Model Design 12

1.2.6 Market Size/Share Estimation 13

1.2.7 Research Limitations 14

1.3 Executive Summary 15

2 Market Overview and Dynamics 17

2.1 Market Size and Forecast 17

2.1.1 Impact of COVID-19 on World Economy 18

2.1.2 Impact of COVID-19 on the Market 20

2.2 Major Growth Drivers 22

2.3 Market Restraints and Challenges 26

2.4 Emerging Opportunities and Market Trends 29

2.5 Porter's Fiver Forces Analysis 33

3 Segmentation of Europe Market by Treatment Type 37

3.1 Market Overview by Treatment Type 37

3.2 Medication 39

3.3 Stem Cell Therapy 41

3.4 Other Treatments 42

4 Segmentation of Europe Market by ALS Type 43

4.1 Market Overview by ALS Type 43

4.2 Sporadic ALS 45

4.3 Familial ALS 46

5 Segmentation of Europe Market by Distribution Channel 47

5.1 Market Overview by Distribution Channel 47

5.2 Hospital Pharmacies 49

5.3 Retail Pharmacies 50

5.4 Online Pharmacies 51

5.5 Other Distribution Channels 52

6 European Market 2020-2027 by Country 53

6.1 Overview of European Market 53

6.2 UK 56

6.3 France 58

6.4 Germany 60

6.5 Spain 62

6.6 Italy 64

6.7 Russia 66

6.8 Rest of European Market 68

7 Competitive Landscape 70

7.1 Overview of Key Vendors 70

7.2 New Product Launch, Partnership, Investment, and M&A 73

7.3 Company Profiles 74

AB Science SA 74

Amylyx Pharmaceuticals Inc. 76

Biogen Inc. 77

Biohaven Pharmaceutical Holding Co., Ltd. 78

BrainStorm Cell Limited 79

Corestem, Inc. 80

F.Hoffmann-La Roche AG 81

Ionis Pharmaceuticals, Inc. 82

Mitsubishi Tanabe Pharma Corporation 83

Otsuka Pharmaceutical Co., Ltd. 84

Sun Pharmaceutical Industries Ltd. 85

RELATED REPORTS 86

 


List Of Figure

Figure 1. Research Method Flow Chart 10

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 13

Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 15

Figure 4. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, USD mn 17

Figure 5. Impact of COVID-19 on Business 20

Figure 6. Primary Drivers and Impact Factors of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 22

Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 25

Figure 8. Primary Restraints and Impact Factors of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 26

Figure 9. Investment Opportunity Analysis 30

Figure 10. Porter's Fiver Forces Analysis of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 33

Figure 11. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2020-2027, % of Revenue 37

Figure 12. Contribution to Europe 2021-2027 Cumulative Revenue by Treatment Type, Value (USD mn) and Share (%) 38

Figure 13. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication, 2017-2027, USD mn 39

Figure 14. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Stem Cell Therapy, 2017-2027, USD mn 41

Figure 15. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Treatments, 2017-2027, USD mn 42

Figure 16. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2020-2027, % of Revenue 43

Figure 17. Contribution to Europe 2021-2027 Cumulative Revenue by ALS Type, Value (USD mn) and Share (%) 44

Figure 18. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Sporadic ALS, 2017-2027, USD mn 45

Figure 19. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Familial ALS, 2017-2027, USD mn 46

Figure 20. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2020-2027, % of Revenue 48

Figure 21. Contribution to Europe 2021-2027 Cumulative Revenue by Distribution Channel, Value (USD mn) and Share (%) 48

Figure 22. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Hospital Pharmacies, 2017-2027, USD mn 49

Figure 23. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Retail Pharmacies, 2017-2027, USD mn 50

Figure 24. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Online Pharmacies, 2017-2027, USD mn 51

Figure 25. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Distribution Channels, 2017-2027, USD mn 52

Figure 26. Breakdown of European Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue 54

Figure 27. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value (USD mn) and Share (%) 55

Figure 28. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in UK, 2017-2027, USD mn 56

Figure 29. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in France, 2017-2027, USD mn 58

Figure 30. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Germany, 2017-2027, USD mn 60

Figure 31. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Spain, 2017-2027, USD mn 62

Figure 32. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Italy, 2017-2027, USD mn 64

Figure 33. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Russia, 2017-2027, USD mn 66

Figure 34. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe, 2017-2027, USD mn 68

Figure 35. Growth Stage of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Industry over the Forecast Period 70


List Of Table

Table 1. Snapshot of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Balanced Perspective, 2020-2027 16

Table 2. Growth Rate of World GDP, 2020-2022 19

Table 3. Main Product Trends and Market Opportunities in Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 29

Table 4. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 37

Table 5. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication by Type, 2017-2027, USD mn 40

Table 6. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 43

Table 7. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 47

Table 8. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, USD mn 55

Table 9. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 57

Table 10. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 57

Table 11. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 57

Table 12. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 59

Table 13. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 59

Table 14. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 59

Table 15. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 61

Table 16. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 61

Table 17. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 61

Table 18. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 63

Table 19. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 63

Table 20. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 63

Table 21. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 65

Table 22. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 65

Table 23. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 65

Table 24. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, USD mn 67

Table 25. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, USD mn 67

Table 26. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, USD mn 67

Table 27. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe by Country, 2017-2027, USD mn 69

Table 28. AB Science SA: Company Snapshot 74

Table 29. AB Science SA: Business Segmentation 74

Table 30. AB Science SA: Product Portfolio 75

Table 31. AB Science SA: Revenue, 2017-2019, USD mn 75

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AB Science SA

Amylyx Pharmaceuticals Inc.

Biogen Inc.

Biohaven Pharmaceutical Holding Co., Ltd.

BrainStorm Cell Limited

Corestem, Inc.

F.Hoffmann-La Roche AG

Ionis Pharmaceuticals, Inc.

Mitsubishi Tanabe Pharma Corporation

Otsuka Pharmaceutical Co., Ltd.

Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)